SCHEMBL23215816

SCHEMBL23215816

CCC(=O)Oc1ccc(O)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.47
ACHE P22303 1/20 0.43
KMT2A Q03164 4/20 0.40
HSD17B10 Q99714 3/20 0.40
KDM4E B2RXH2 2/20 0.40
GLA P06280 2/20 0.40
GAA P10253 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
ESR1 P03372 2/20 0.40
HIF1A Q16665 2/20 0.40
HSP90AB1 P08238 1/20 0.40
ACLY P53396 1/20 0.39
FGFR1 P11362 1/20 0.39
VCP P55072 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1994886 0.84 ALOX15 (0.49) ALOX15ACHEKMT2AHSD17B10KDM4E
SCHEMBL14274168 0.83 ALOX15 (0.47) ALOX15ACHEKMT2AHSD17B10KDM4E
SCHEMBL28169742 0.82 ALOX15 (0.50) ALOX15ACHEKMT2AHSD17B10KDM4E
SCHEMBL25797727 0.82 ALOX15 (0.52) ALOX15KMT2AKDM4EMEN1HTT
SCHEMBL25798003 0.81 ALOX15 (0.41) ALOX15KMT2AKDM4ELMNAMEN1
SCHEMBL5965056 0.81 ALOX15 (0.46) ALOX15ACHEKMT2AHSD17B10KDM4E
SCHEMBL19774166 0.81 ACHE (0.51) ALOX15ACHEKMT2AHSD17B10KDM4E
SCHEMBL12987528 0.80 CYP4F2 (0.49) HSD17B10KDM4EGAAHPGDLMNA
SCHEMBL6816782 0.80 MAPT (0.49) ALOX15KMT2AKDM4EGAAHPGD
SCHEMBL15110131 0.80 CYP4F2 (0.54) ALOX15ACHEKMT2AHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217983-A1 GPR119 AGONISTS KALLYOPE, INC. 2024-07-04 US disclosed
EP-4320129-A1 GPR119 AGONISTS Kallyope, Inc. (US) 2024-02-14 EP disclosed
US-20230061736-A1 GPR119 AGONISTS KALLYOPE, INC. 2023-03-02 US disclosed
CN-114945560-A GPR119 agonists 卡尔优普公司 2022-08-26 CN disclosed
US-20220153719-A1 GPR119 AGONISTS KALLYOPE, INC. 2022-05-19 US disclosed
WO-2021071837-A1 GPR119 AGONISTS KALLYOPE, INC. (US) 2021-04-15 WO disclosed
CN-102131778-A Heterocyclic gpcr agonists PROSIDION LTD 2011-07-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217983-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR ALOX15 900/4885ACHE 2924/4885KMT2A 1503/4885
US-20230061736-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR ALOX15 900/4885ACHE 2924/4885KMT2A 1503/4885
US-20220153719-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR ALOX15 900/4885ACHE 2924/4885KMT2A 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.